In the preceding three months, 10 analysts have released ratings for Dentsply Sirona XRAY, presenting a wide array of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 5 | 4 | 0 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 3 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 1 | 2 | 3 | 0 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $32.5, a high estimate of $38.00, and a low estimate of $27.00. Observing a downward trend, the current average is 9.22% lower than the prior average price target of $35.80.
Deciphering Analyst Ratings: An In-Depth Analysis
A clear picture of Dentsply Sirona's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Jonathan Block | Stifel | Lowers | Hold | $28.00 | $30.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $27.00 | $28.00 |
| Michael Petusky | Barrington Research | Maintains | Outperform | $38.00 | $38.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $28.00 | $35.00 |
| Nathan Rich | Goldman Sachs | Lowers | Neutral | $30.00 | $34.00 |
| Elizabeth Anderson | Evercore ISI Group | Lowers | Outperform | $35.00 | $40.00 |
| Michael Petusky | Barrington Research | Lowers | Outperform | $38.00 | $41.00 |
| Jason Bednar | Piper Sandler | Lowers | Neutral | $32.00 | $35.00 |
| Jeffrey Johnson | Baird | Lowers | Neutral | $33.00 | $35.00 |
| David Saxon | Needham | Lowers | Buy | $36.00 | $42.00 |
Key Insights:
- Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Dentsply Sirona. This insight gives a snapshot of analysts' perspectives on the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dentsply Sirona compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of Dentsply Sirona's stock. This comparison reveals trends in analysts' expectations over time.
To gain a panoramic view of Dentsply Sirona's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on Dentsply Sirona analyst ratings.
About Dentsply Sirona
Dentsply Sirona is one of the world's largest manufacturers of dental equipment and supplies. It is a result of a merger of equals in 2016 between Dentsply International (manufactured dental consumables and lab products) and Sirona Dental Systems (manufactured technologically-advanced dental equipment). The firm's wide portfolio consists of dental consumables, lab products, CAD/CAM and imaging technology, medical devices, and specialty products in orthodontics, endodontics, and implantation. It distributes two-thirds of its dental consumables, technology and equipment through third-party distributors and the remaining portfolio is either sold to labs and offices through the firm's salesforce or directly to consumers (such as Byte clear aligner).
A Deep Dive into Dentsply Sirona's Financials
Market Capitalization Analysis: The company's market capitalization surpasses industry averages, showcasing a dominant size relative to peers and suggesting a strong market position.
Revenue Growth: Dentsply Sirona's revenue growth over a period of 3 months has faced challenges. As of 31 March, 2024, the company experienced a revenue decline of approximately -2.56%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Dentsply Sirona's net margin excels beyond industry benchmarks, reaching 1.89%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Dentsply Sirona's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 0.55%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Dentsply Sirona's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.25% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Dentsply Sirona's debt-to-equity ratio is below the industry average at 0.68, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Core of Analyst Ratings: What Every Investor Should Know
Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in Benzinga Pro.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
